Telatinib

Base Information

• Chemical Name: Telatinib
• CAS No.: 332012-40-5
• Molecular Formula: C20H16ClN5O3
• Molecular Weight: 409.832
• UNII: 18P7197Q7J
• DSSTox Substance ID: DTXSID70954809
• Wikidata: Q27252023
• NCI Thesaurus Code: C80869
• Pharos Ligand ID: RSCYZG1GCZVF
• Metabolomics Workbench ID: 155463
• ChEMBL ID: CHEMBL2079588
• Mol file: 332012-40-5.mol

Synonyms:4-(((4-((4-chlorphenyl)amino)furo(2,3-d)pyridazin-7-yl)oxy)methyl)-N-methylpyridine-2-carboxamide;BAY 57-9352;telatinib

Chemical Property of Telatinib

Chemical Property:

• Boiling Point: 713.595 °C at 760 mmHg
• PKA: 14.18±0.46(Predicted)
• Flash Point: 385.368 °C
• PSA: 102.17000
• Density: 1.418 g/cm³
• LogP: 4.41730
• Solubility.: insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL in DMSO
• XLogP3: 3.1
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 7
• Rotatable Bond Count: 6
• Exact Mass: 409.0941671
• Heavy Atom Count: 29
• Complexity: 548

Purity/Quality:

98%,99%, ^*data from raw suppliers

Telatinib ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CNC(=O)C1=NC=CC(=C1)COC2=NN=C(C3=C2OC=C3)NC4=CC=C(C=C4)Cl
• Recent ClinicalTrials: Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
• Recent EU Clinical Trials: A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination with Chemotherapy as First-line Therapy in Subjects with Advanced Gastric Cancer
• Description: Telatinib is a multi-kinase inhibitor that inhibits VEGF receptor 2 (VEGFR2), VEGFR3, PDGFRα, and c-Kit (IC50s = 6, 4, 15, and 1 nM, respectively). It also binds to the transmembrane region of the ABCG2 efflux transporter and enhances intracellular accumulation of [3H]-mitoxantrone in ABCG2-overexpressing cells. Telatinib (15 mg/kg) decreases tumor growth rate and size in an H460/MX20 mouse xenograft model.
• Uses: Telatinib (BAY 57-9352) is an orally available, potent multitargeted VEGFR-2, VEGFR-3, PDGFR-β and c-Kit tyrosine kinases inhibitor with an IC50 of 19 nM for the inhibition of VEGFR-2 autophosphorylation. Telatinib small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases. Telatinib is used therapeuticall y in patients with advanced solid tumors. Telatinib small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases. Telatinib is used therapeutically in patients with advanced solid tumors.

Technology Process of Telatinib

There total 17 articles about Telatinib which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 46.0%

4-(hydroxymethyl)-N-methylpyridine-2-carboxamide (332013-43-1) + 4-chloro-7-[N-(4-chlorophenyl)amino]-[2,3-d]furopyridazine (332013-41-9) → Telatinib (332012-40-5)

Guidance literature:

With potassium hydroxide; 18-crown-6 ether; In toluene; at 20 - 87 ℃; Product distribution / selectivity;

Reference yield: 46.0%

4-(hydroxymethyl)-N-methylpyridine-2-carboxamide (332013-43-1) + 4-chloroanilino-7-chlorofuro[2,3-d]pyridazine (332013-40-8) → Telatinib (332012-40-5)

Guidance literature:

With potassium hydroxide; 18-crown-6 ether; In toluene; at 83 - 87 ℃; Product distribution / selectivity;

Reference yield: 37.7%

4-chloroanilino-7-chlorofuro[2,3-d]pyridazine (332013-40-8) + 2-methylaminocarbonyl-4-pyridylcarbinol hydrochloride (1182334-19-5) → Telatinib (332012-40-5)

Guidance literature:

With potassium tert-butylate; In tetrahydrofuran; toluene; at 95 ℃; for 24h; Temperature; Time; Autoclave;

upstream raw materials:

N-Methylformamide

4-(hydroxymethyl)-N-methylpyridine-2-carboxamide

4-chloroanilino-7-chlorofuro[2,3-d]pyridazine

4-chloro-7-[N-(4-chlorophenyl)amino]-[2,3-d]furopyridazine

Downstream raw materials:

4-[({4-[(4-chlorophenyl)amino]furan[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide methanesulfonate

4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide 4-methylbenzenesulfonate

Refernces

• 1、 -. "SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY". Page/Page column 45. . Retrieved 2009/03/07.
• 2、 -. "Substituted pyridines and pyridazines with angiogenesis inhibiting activity". Page column 60-61. . Retrieved 2010/02/05.